[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"arthritis-shoulder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:arthritis-shoulder":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,83,109,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100586828","zimmer-biomet-shoulder-arthroplasty-pmcf-study-100586828",false,"NCT06920459","Zimmer Biomet Shoulder Arthroplasty PMCF Study","Zimmer Biomet Shoulder Arthroplasty Long-term Post Market Clinical Follow-up Study","Inclusion Criteria:\n\n* Patient must be 20 years of age or older.\n* Patient must be anatomically and structurally suited to receive shoulder arthroplasty implants.\n* Patient is a candidate for shoulder arthroplasty due to one or more of the following:\n\nNon-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis.\n\nRheumatoid arthritis. Fractures of the proximal humerus, where other methods of treatment are deemed inadequate.\n\nDifficult clinical management problems, where other method of treatment may not be suitable or may be inadequate.\n\n* Patient must be able and willing to complete the protocol required follow-up.\n* Patient must be able and willing to sign the IRB\u002FEC approved informed consent.\n\nExclusion Criteria:\n\n* Patient is unwilling or unable to give consent or to comply with the follow-up program.\n* Patient has any condition which would in the judgement of the Investigator, place the patient at undue risk or interfere with the study.\n* Patient is known to be pregnant or breastfeeding.\n* Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, and\u002For anticipated to be non- compliant).\n* Patient is uncooperative or patient with neurologic disorders who is incapable or unwilling to follow directions.\n* Patient has any sign of infection affecting the shoulder joint or in its proximity which may spread to the implant site.\n* Patient has rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram.\n* Patient has any neuromuscular disease compromising the affected limb that would render the procedure unjustifiable.\n* Patient presents with osteoporosis, which in the opinion of the Investigator, may limit the subject's ability to support total shoulder arthroplasty using the study device.\n* Patient has a metabolic disorder that may impair bone formation.\n* Patient has osteomalacia.","ALL","20 Years",{"count":19,"type":20},50,"ESTIMATED","OBSERVATIONAL","This is a multicenter, prospective, non-controlled post market surveillance study. The objectives of this study are to confirm the safety, performance, and clinical benefits of the Zimmer Biomet Shoulder Arthroplasty systems in primary anatomic shoulder arthroplasty and its instrumentation. Safety of the systems will be assessed by monitoring the frequency and incidence of adverse events. The performance and clinical benefits will be evaluated by assessment of the overall pain and functional performance, qualify of life, and radiographic parameters of all enrolled study subjects.",[24,25,26,27,28,29],"Shoulder Fractures","Shoulder Arthritis Osteoarthritis","Shoulder Injury","Shoulder Pain","Degenerative Joint Disease","Arthritis Shoulder",[31,32,33],"medical device","PMCF","Anatomic Total Shoulder Arthroplasty","RECRUITING","2026-06-05",{"date":37,"type":38},"2026-06-08","ACTUAL",{"date":40,"type":38},"2025-04-29",{"date":42,"type":20},"2037-06",{"name":44,"class":45},"Zimmer Biomet","INDUSTRY",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100410813","anatomic-tsa-vs-rtsa-for-glenohumeral-arthritis-100410813","NCT04629391","Anatomic TSA vs RTSA for Glenohumeral Arthritis","Anatomic Versus Reverse Shoulder Arthroplasty for Primary Glenohumeral Osteoarthritis. A Randomized Prospective Study","Inclusion Criteria:\n\n* Primary glenohumeral arthritis,\n* Intact rotator cuff,\n* No important glenoid bone loss (cf exclusion criteria),\n* Patients between 65 and 85 years old\n* Informed Consent as documented by signature (Appendix Informed Consent Form).\n\nExclusion Criteria:\n\n* B2 glenoid with \\> 80% posterior humeral head subluxation or greater 25 degrees neoglenoid retroversion,\n* B3 and C type glenoids,\n* Full thickness rotator cuff tear,\n* Acute or malunited proximal humeral fracture,\n* Chronic locked dislocation\n* Rheumatoid arthritis,\n* Revision surgery or surgical antecedents,\n* Tumors,\n* Axillary nerve damage,\n* Non-functioning deltoid muscle,\n* Glenoid vault deficiency precluding baseplate fixation,\n* Infection and neuropathic joints,\n* Known or suspected non-compliance, drug or alcohol abuse,\n* Patients incapable of judgement or under tutelage,\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, contraindication for CT scan etc. of the participant,\n* Enrolment of the investigator, his\u002Fher family members, employees and other dependent persons.","65 Years","85 Years",{"count":57,"type":20},296,"INTERVENTIONAL",[60],"NA","There are no published prospective studies that compared 2-year functional outcomes of RTSA and anatomic TSA for the treatment of primary glenohumeral osteoarthritis with intact rotator cuffs and no excessive glenoid retroversion. The primary goal of our prospective randomized study is to determine whether RTSA have at least as good results as anatomic TSA (non-inferiority), in patients with glenohumeral osteoarthritis, without rotator cuff tears nor significant glenoid retroversion.",[29],[64,65,66,67,68,69,70,71],"shoulder","primary osteoarthritis","Range of motion","clinical outcomes","radiographic outcomes","anatomic prosthesis","reverse prosthesis","Arthroplasty","2026-05-19",{"date":74,"type":38},"2026-05-22",{"date":76,"type":38},"2020-09-01",{"date":78,"type":20},"2027-05-01",{"name":80,"class":81},"La Tour Hospital","OTHER",1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":90,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":58,"phases":93,"briefSummary":94,"conditions":95,"keywords":96,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":82},"100418405","comparison-of-lateralized-rtsa-with-and-without-subscapularis-repair-100418405","NCT04728282","Comparison of Lateralized RTSA With and Without Subscapularis Repair","Randomized Clinical Trial Comparing Lateralized Reverse Total Shoulder Arthroplasty (RTSA) With and Without Subscapularis Repair","Inclusion Criteria:\n\n* Clinical diagnosis of glenohumeral arthritis, rotator cuff arthropathy, or massive irreparable rotator cuff tear with surgeon-patient decision to undergo RTSA\n* First RTSA implantation\n* Absence of neoplastic diseases at the treated site\n* Fatty infiltration of the subscapularis is low-grade (i.e. Goutallier \\\u003C Grade 3) based on pre-operative CT performed as standard of care in the patient group\n\nExclusion Criteria:\n\n* Previous shoulder arthroplasty (hemi-, total shoulder, or RTSA)\n* Avascular necrosis\n* Post-infectious arthritis\n* Proximal humerus fracture\n* Inflammatory arthritis\n* Inability to communicate in English\n* Unable to return for study visits to 24-months post-operative (e.g. unable to arrange transportation to study appointments, plans to relocate, etc.)\n\nIntra-operative Exclusions:\n\n* Subscapularis with fatty infiltration (Goutallier ≥ 3)\n* Subscapularis that is deemed to be irreparable. An irreparable tendon is defined as one that is not of sufficient quality or does not allow adequate excursion to reach the repair site\n* Any anatomical or patient characteristic that warrants a non-lateralized implant","18 Years",{"count":92,"type":20},284,[60],"The purpose of this double-blind randomized controlled trial is to compare patient-reported, clinical, and functional outcomes in patients undergoing RTSA with and without subscapularis repair after placement of a modern \"lateralized\" implant over the course of 24-months postoperative.",[29],[97,98,99],"reverse total shoulder arthroplasty","subscapularis","repair","2026-02-23",{"date":102,"type":38},"2026-02-25",{"date":104,"type":38},"2021-11-01",{"date":106,"type":20},"2030-03-01",{"name":108,"class":81},"Panam Clinic",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":90,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":58,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":82},"100435352","efficacy-of-intra-articular-injections-for-the-treatment-of-primary-glenohumeral-osteoarthritisghoa-100435352","NCT04949087","Efficacy of Intra-articular Injections for the Treatment of Primary Glenohumeral Osteoarthritis(GHOA)","Prospective, Double Blind, Randomized Control Trial Comparing the Efficacy of Intra-articular Injections for the Treatment of Primary Glenohumeral Osteoarthritis","GHOA","Inclusion Criteria:\n\n* Patient ≥18y.o. of age\n* Primary glenohumeral arthritis (bone on bone or near bone on bone) that has been previously diagnosed on radiographs and clinical evaluation.\n* Baseline pain level of VAS \\>4\n\nExclusion Criteria:\n\n* Secondary causes of arthritis (i.e. septic arthritis, rheumatoid arthritis, rotator cuff arthropathy, post-traumatic arthritis)\n* Ipsilateral shoulder surgery within 1 year\n* Any glenohumeral joint injection within 3 months\n* Allergy to lidocaine\n* Known pregnancy\n* Workers compensation case regarding shoulder",{"count":118,"type":20},200,[60],"The purpose of this study is to compare the efficacy of intra-articular corticosteroid injections versus platelet-rich plasma injections for non-operative treatment of primary glenohumeral osteoarthritis. The efficacy of intra-articular injections, outside of hyaluronic acid, for the treatment of glenohumeral OA is not known, yet these treatments are commonly used with hopes of providing patients with symptomatic relief that can hopefully delay or prevent the need for shoulder arthroplasty. This study will help elucidate the therapeutic benefit of corticosteroid and Platelet Rich Plasma (PRP) injections in this patient population.",[29],"2026-02-11",{"date":124,"type":38},"2026-02-17",{"date":126,"type":38},"2023-03-13",{"date":128,"type":20},"2028-01",{"name":130,"class":81},"Rush University Medical Center",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":90,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":58,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":46},"100444040","mirror-medacta-shoulder-system-pivotal-trial-100444040","NCT05062252","Mirror Medacta Shoulder System Pivotal Trial","Multicentric, Prospective, Comparative Trial to Assess the Efficacy and Safety of an Anatomic Total Shoulder System.","Inclusion Criteria:\n\n* Age ≥ 18 yr\n* Clinical indication for anatomic primary total shoulder replacement due to osteoarthritis and\u002For posttraumatic arthritis\n* Willingness and ability to comply with study protocol\n\nExclusion Criteria:\n\n* Medical condition or balance impairment that could lead to falls\n* Prior rotator cuff surgery\n* Cuff tear arthropathy\u002Finsufficient rotator cuff\n* Insufficient bone quality which may affect the stability of the implant\n* Neuromuscular compromise of shoulder or other disabilities affecting the maximum functional outcomes\n* Weight bearing shoulder due to wheel chair, crutches, rollator at the time of operation\n* Active metastatic or neoplastic disease at the shoulder joint\n* Chemotherapy treatment\u002Fradiotherapy within 6 mo before surgery\n* \\>5 mg\u002Fday of corticosteroids, excluding inhalers, within 3 years before surgery\n* Pregnancy or plan to become pregnant during study period\n* Inability to understand study or a history of noncompliance with medical advice\n* Alcohol or drug abuse\n* Current enrollment in any clinical research study that might interfere with this study\n* Metal allergies or sensitivity.\n* Previous or current infection at or near the site of implantation.\n* Current distant or systemic infection\n* Patient, whose infomed consent form should be taken in an emergency situation\n* ONLY for women of childbearing age: a positive pregnancy test (urine \u002F blood)",{"count":139,"type":20},100,[60],"The purpose of this study is to demonstrate safety and efficacy of the Mirror Medacta Shoulder System in total shoulder arthroplasty.",[29,143],"Post-traumatic Arthrosis of Other Joints, Upper Arm","2025-05-07",{"date":146,"type":38},"2025-05-08",{"date":148,"type":38},"2022-01-05",{"date":150,"type":20},"2027-12-30",{"name":152,"class":45},"Medacta International SA"]